



DEPARTMENT OF HEALTH & HUMAN SERVICES

---

Food and Drug Administration  
Rockville MD 20857

MAY 22 2007

Re: Lunesta  
Docket No.: 2005E-0255

The Honorable Jon Dudas  
Undersecretary of Commerce for Intellectual Property  
Director of the United States Patent and Trademark Office  
Mail Stop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Director Dudas:

This letter concerns the application for patent term extension for U.S. Patent No. 6,444,673, filed by Sepracor, Inc., under 35 U.S.C. § 156 et seq., and our May 15, 2007, letter determining the regulatory review period for Lunesta (eszopiclone), the human drug product claimed by the patent.

After our letter was issued, we realized that the determination of the regulatory review period for Lunesta was not routine and is affected by issues raised in a pending citizen petition. Consequently, we are withdrawing the May 15, 2007, letter determining the regulatory review period for Lunesta until we have completed our response to the citizen petition. We will respond to your request to determine the applicable regulatory review period as soon as possible after resolving the issues raised in the citizen petition.

We apologize for any inconvenience this may cause. Please let us know if we can be of further assistance.

Sincerely yours,

A handwritten signature in cursive script, reading "Jane A. Axelrad", is positioned above the typed name.

Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Philip E. Hansen  
Heslin Rothenberg Farley & Mesiti, P.C.  
5 Columbia Circle  
Albany, NY 12203-5160